Q32 Bio Inc.
QTTB
$3.61
$0.205.87%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -224.35% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -224.35% |
| Cost of Revenue | -36.95% | 55.62% | 6.53% | -19.84% | -28.70% |
| Gross Profit | 61.35% | 12.74% | 23.92% | 33.73% | -82.26% |
| SG&A Expenses | 1.97% | 21.02% | 44.87% | 81.86% | 75.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -32.12% | 0.46% | 35.63% | 58.88% | 48.82% |
| Operating Income | 44.98% | 18.92% | -12.27% | -36.98% | -154.92% |
| Income Before Tax | 27.60% | 4.97% | -34.77% | 7.65% | -66.36% |
| Income Tax Expenses | -733.99% | -604.40% | -604.40% | -604.40% | 208.54% |
| Earnings from Continuing Operations | 30.54% | 8.31% | -30.34% | 11.18% | -66.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 30.54% | 8.31% | -30.34% | 11.18% | -66.68% |
| EBIT | 44.98% | 18.92% | -12.27% | -36.98% | -154.92% |
| EBITDA | 45.18% | 19.00% | -12.40% | -37.40% | -157.57% |
| EPS Basic | 95.59% | 96.33% | 96.27% | 98.04% | 0.23% |
| Normalized Basic EPS | 92.00% | 94.28% | 94.48% | 96.71% | 23.25% |
| EPS Diluted | 95.97% | 96.54% | 96.46% | 93.24% | -9.16% |
| Normalized Diluted EPS | 92.07% | 94.31% | 94.51% | 96.27% | 22.49% |
| Average Basic Shares Outstanding | 92.26% | 256.16% | 2,268.95% | 2,571.30% | 210.42% |
| Average Diluted Shares Outstanding | 82.63% | 224.37% | 1,331.33% | 2,667.41% | 226.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |